Akari Therapeutics, Plc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $13.7M
- Price
- $7.85
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.77%
- Volume
- 11.0K
About
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Quick stats
Shares outstanding1.8M
Computed float1.9M
Float / shares108.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001541157
Websitehttps://www.akaritx.com
AI Summary
AI-generated1/28
standardbullishclinical trial
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
Akari Therapeutics announced positive preclinical data for AKTX-101, its TROP2-targeted ADC utilizing a novel PH1 RNA spliceosome-modulating payload.
The data demonstrated statistically significant anti-tumor activity in urothelial cancer models resistant to currently approved ADC therapies like Padcev and Trodelvy, supporting a differentiated sequencing strategy.
The company is advancing IND-enabling activities with a goal of initiating a Phase 1 clinical trial in mid-2027.